Objective-Micromolar concentrations of the proangiogenic metabolite deoxyribose-1-phosphate (dRP) were detected in platelet supernatants by mass spectrometry. In this study, we assessed whether the release of dRP by platelets stimulates endothelial cell migration and angiogenesis. Methods and Results-Protein-free supernatants from thrombin-stimulated platelets increased human umbilical vein endothelial cell migratory activity in transmigration and monolayer repair assays. This phenomenon was ablated by genetic silencing of dRP-generating uridine phosphorylase (UP) and thymidine phosphorylase (TP) or pharmacological inhibition of UP and restored by exogenous dRP. The stimulation of endothelial cell migration by platelet-derived dRP correlated with upregulation of integrin ␤ 3 , which was induced in a reactive oxygen species-dependent manner, and was mediated by the activity of the integrin heterodimer ␣ v ␤ 3 . The physiological relevance of dRP release by platelets was confirmed in a chick chorioallantoic membrane assay, where the presence of this metabolite in platelet supernatants strongly induced capillary formation. Key Words: angiogenesis Ⅲ endothelium Ⅲ platelets Ⅲ reactive oxygen species Ⅲ deoxyribose-1-phosphate B esides their well-established physiological role in hemostasis, platelets are known to release paracrine factors that facilitate vascular repair and angiogenesis, 1-3 and platelet-based preparations (eg, autologous platelet preparation, platelet-rich plasma, and platelet-derived wound healing formula) have been investigated for their proangiogenic potential and used for tissue regenerative purposes in clinical practice. 4,5 Platelet-derived angiogenic factors, including basic fibroblast growth factor and vascular endothelial growth factor (VEGF), have been shown to stimulate angiogenesis in vitro by enhancing both endothelial cell motility 1 and proliferation. 6 Similarly, heparanase, platelet-derived growth factor, and stromal cell-derived factor 1␣, all of which are released by activated platelets, can increase endothelial motility and angiogenesis, 1,7-9 and there is also evidence that platelet-derived stromal cell-derived factor 1␣ directly promotes migration and differentiation of endothelial progenitor cells. 10, 11 With the exception of platelet-derived sphingosine-1-phosphate, which stimulates endothelial cell migration and angiogenesis by upregulating the expression of adhesion molecules, 12 the majority of research in this area has focused on platelet secretion of protein factors.
B
esides their well-established physiological role in hemostasis, platelets are known to release paracrine factors that facilitate vascular repair and angiogenesis, [1] [2] [3] and platelet-based preparations (eg, autologous platelet preparation, platelet-rich plasma, and platelet-derived wound healing formula) have been investigated for their proangiogenic potential and used for tissue regenerative purposes in clinical practice. 4, 5 Platelet-derived angiogenic factors, including basic fibroblast growth factor and vascular endothelial growth factor (VEGF), have been shown to stimulate angiogenesis in vitro by enhancing both endothelial cell motility 1 and proliferation. 6 Similarly, heparanase, platelet-derived growth factor, and stromal cell-derived factor 1␣, all of which are released by activated platelets, can increase endothelial motility and angiogenesis, 1, [7] [8] [9] and there is also evidence that platelet-derived stromal cell-derived factor 1␣ directly promotes migration and differentiation of endothelial progenitor cells. 10, 11 With the exception of platelet-derived sphingosine-1-phosphate, which stimulates endothelial cell migration and angiogenesis by upregulating the expression of adhesion molecules, 12 the majority of research in this area has focused on platelet secretion of protein factors.
Here, we present evidence that platelets release lowmolecular-mass molecules (Ͻ2 kDa) that are capable of stimulating endothelial cell migration, a key component of angiogenesis. 13 Small molecules released into platelet supernatants were characterized by gas chromatography-mass spectrometry (GC-MS) and direct injection-mass spectrometry (DIMS), which revealed the presence of deoxyribose-1-phosphate (dRP), a known proangiogenic molecule that stimulates endothelial cell migration. 14 -16 dRP is the product of the phosphorolytic degradation of deoxynucleosides in the "nucleotide salvage pathway," which is catalyzed by 3 enzymes in mammalian cells: thymidine phosphorylase (TP, or platelet-derived endothelial cell growth factor, EC 2.4.2.4), uridine phosphorylase (UP, EC 2.4.2.3), and purine nucleoside phosphorylase (PNP, EC 2.4.2.1). 17 We have used pharmacological inhibitors of TP, UP, or PNP in human platelets and the genetic ablation of TP and UP in mouse platelets to investigate whether platelet-derived dRP stimu-lates human endothelial cell motility and angiogenesis. Taken together, our results show for the first time that plateletderived dRP induces the upregulation of endothelial integrin ␤ 3 in a reactive oxygen species (ROS)-dependent manner, leading to increased endothelial cell motility in vitro and angiogenesis in vivo. These observations highlight a novel function of platelets in the regulation of vascular homeostasis and may facilitate the development of novel therapeutic approaches for modulating angiogenesis and tissue repair.
Methods
A concise description of the experimental procedures is presented in this section. An expanded Materials and Methods section is available online at http://atvb.ahajournals.org.
Platelet Isolation and Supernatant Preparation
Blood was drawn from healthy volunteers with the approval of the local ethics committee or from wild-type (WT) and TP Ϫ/Ϫ /UP Ϫ/Ϫ mice, generated as previously described. 18 Washed platelets were prepared as previously described. 19 Where indicated, platelets were stimulated with human thrombin (0.1 unit/mL for human platelets; 1 unit/mL for mouse platelets) for 5 minutes.
GC-MS and DIMS
In preparation for the mass spectrometry analysis, supernatants were obtained without permeabilization by precipitation of platelet suspensions (1000 g), followed by separation from platelet pellets and filtration (2-kDa cutoff). Detailed methods for GC-MS and DIMS are given in the supplemental materials.
Endothelial Cell Transmigration and Endothelial Monolayer Repair Assays
For transmigration assays, 10 5 human umbilical vein endothelial cells (HUVECs)/well (medium M-199 plus Tyrode HEPES buffer; ratio, 1:1; final FCS concentration, 5%) were plated onto 24-well transmigration inserts (membrane pore size, 8 m) precoated with 1% gelatin. The lower chamber contained medium M-199 plus protein-free platelet supernatant or Tyrode HEPES buffer (ratio, 1:1; final FCS concentration, 5%). Transmigration was quantified 5 hours after assembly of the chemotaxis microchamber by hematoxylin staining and phase-contrast microscopy.
For endothelial monolayer repair assays, HUVECs were cultured to confluence in 12-well plates. A uniform wound was created by scratching the cell monolayer with a microtip, and medium M-199 plus platelet supernatant or Tyrode HEPES buffer was added (ratio, 2:1; final FCS concentration, 6.6%). Wound surface area was monitored at 0, 12, and 24 hours after wounding by phase contrast microscopy.
ROS Production Assay
The generation of ROS in HUVECs was investigated using dihydroethidium staining and real-time single-cell fluorescence analysis, as previously described. 20 
Chick Chorioallantoic Membrane Assay
On day 7 of development, sterile filters soaked with vehicle, VEGF, or the appropriate protein-free platelet supernatant were applied to relatively avascular regions of the chick chorioallantoic membrane (CAM). The newly capillarized area in the region of each filter was quantified after 48 hours.
Statistical Analysis
Data are expressed throughout as meanϮSEM. The results were analyzed by t test (for comparisons of 2 groups), 1-way ANOVA with the Bonferroni post test (for multiple comparisons), or 2-way ANOVA with the Bonferroni post test (for multiple comparisons of time courses).
Results
Initial characterization by GC-MS of human platelet supernatants revealed the presence of dRP, a proangiogenic molecule. 14 -16 The presence of this metabolite in platelet supernatants was confirmed using a dRP standard ( Figure 1A) , and showing platelet extracts and a commercially available dRP standard. The dRP content of human platelet supernatants (B) or whole cell extracts (C) was investigated further by DIMS (from 4 mL of platelet suspension). Thrombinstimulated platelets were compared with resting platelets or plasma. The statistical significance of the differences was tested by 1-way ANOVA or t test (*PϽ0.05, nϭ5).
platelet expression of dRP-generating enzymes (TP, UP, and PNP) was established by immunoblotting (Supplemental Figure I ). These data showed that human platelets express all 3 nucleoside phosphorylases, whereas mouse platelets express TP and UP but not PNP, and HUVECs express PNP at high levels and UP at low levels but no TP. The pattern of dRP secretion was then investigated by DIMS, which allows the relative quantitative determination of the ions, thus permitting a relative estimation of the change in concentration of the originating molecules (Supplemental Figure II) . Thrombin stimulation significantly increased the release of dRP by platelets ( Figure 1B ) while decreasing its levels within platelets (platelet extracts, Figure 1C ), suggesting a storage-release mechanism rather than de novo synthesis on stimulation. Exposure of human platelets to collagen (10 g/mL) also significantly increased the release of dRP, whereas the thromboxane A2 analog U46619 (100 nmol/L) did not (Supplemental Figure IIIA) . On the basis of the sensitivity of the experimental procedure and equipment used, the concentration of dRP in platelet supernatants is estimated to be in the micromolar range (50 to 400 mol/L). Interestingly, the level of dRP in human plasma is approximately 1/10th that in platelet supernatants ( Figure 1B ), suggesting that activated platelets are likely to change local concentrations of this metabolite at sites of vascular injury.
The functional relevance of dRP release by platelets was assessed in transmigration experiments using protein-free platelet supernatants ( Figure 2A ). Filtration (2-kDa cutoff), which eliminated membrane bodies, proteins, and nucleic acids from platelet supernatants, reduced but did not abolish the promigratory activity of thrombin-stimulated platelet supernatants ( Figure 2B ), suggesting that platelet stimulation leads to the release of small molecules (Ͻ2 kDa) able to promote endothelial cell transmigration. To assess the importance of dRP in the stimulation of endothelial cell motility by platelet supernatants, protein-free supernatants from thrombin-stimulated mouse platelets were used. As expected, platelet supernatants from TP Ϫ/Ϫ /UP Ϫ/Ϫ mice were characterized by depleted levels of dRP compared with WT platelets (Supplementary Figure IIIB) . Thrombin stimulation of WT platelets significantly increased HUVEC transmigration, whereas the effects of thrombin-stimulated TP Ϫ/Ϫ /UP Ϫ/Ϫ supernatants did not reach statistical significance compared with supernatants from resting platelets ( Figure 2C ). The addition of 200 mol/L dRP to supernatants from TP Ϫ/Ϫ / UP Ϫ/Ϫ platelets significantly increased HUVEC transmigration to levels similar to those of WT platelet supernatants, suggesting that the ablation of dRP is responsible for the lack of HUVEC transmigration observed with TP Ϫ/Ϫ /UP Ϫ/Ϫ supernatants. Human platelets were also used and treated with specific nucleoside phosphorylase inhibitors: 100 mol/L 6-(2-aminoethyl)amino-5-chlorouracil was used as an inhibitor of TP, 21 50 mol/L 5-phenylthiocyclouridine (PTAU) was used to inhibit UP, 22 and the activity of PNP was ablated with 50 mol/L 8-aminoguanosine. Supernatants from resting and thrombin-stimulated platelets treated with inhibitor(s) were used in HUVEC transmigration experiments ( Figure  2D) . PTAU or the simultaneous use of the 3 inhibitors significantly reduced the increase in HUVEC transmigration by protein-free supernatants, whereas the addition of 200 mol/L dRP restored the stimulation of transmigration.
The migratory activity of HUVECs in response to proteinfree platelet supernatants was also examined using a monolayer repair assay. HUVEC monolayers were physically wounded, and wound closure in the presence of protein-free platelet supernatants was measured after 0, 12, and 24 hours (Figure 3) . The rate of closure was significantly faster in the presence of protein-free supernatants from WT mouse platelets compared with vehicle (Tyrode buffer). Protein-free supernatants from TP Ϫ/Ϫ /UP Ϫ/Ϫ platelets showed a significantly reduced ability to accelerate wound closure compared with WT platelet supernatants (even though the rate and extent of wound closure were ameliorated by TP Ϫ/Ϫ /UP Ϫ/Ϫ platelet supernatants compared with vehicle). The addition of 200 mol/L dRP to supernatants from TP Ϫ/Ϫ /UP Ϫ/Ϫ platelets restored HUVEC wound-closure rates to the same levels observed for WT supernatants.
Upregulation of integrin ␤ 3 has been proposed as the molecular mechanism underlying the stimulation of endothelial cell migration by endothelial progenitor cell-derived dRP. 23 In accordance with this previous study, HUVECs cultured in the presence of dRP-depleted protein-free supernatants from thrombin-stimulated TP Ϫ/Ϫ /UP Ϫ/Ϫ platelets expressed significantly lower levels of integrin ␤ 3 compared with HUVECs cultured in the presence of WT supernatants ( Figure 4A and Supplemental Figure IVB Figure IVA and IVB) . Importantly, the dRP-dependent upregulation of integrin ␤ 3 was also observed in human microvascular endothelial cells, suggesting that platelet supernatant stimulates the migratory activity of different endothelial cell types ( Figure 4C and 4D) .
Incubation of HUVECs with dRP accelerated ROS production, as assessed using a dihydroethidium-based assay ( Figure  4E ). The generation of ROS by platelet-derived dRP was also confirmed by immunoblotting for heme oxygenase-1 (HO-1, or heat shock protein 32), a protein known to be upregulated in response to ROS generation in endothelial cells. 24 As expected, supernatants from WT platelets increased HO-1 expression, whereas supernatants from TP Ϫ/Ϫ /UP Ϫ/Ϫ platelets did not ( Figure 4F ). The addition of exogenous dRP restored the upregulation of HO-1 in HUVECs exposed to TP Ϫ/Ϫ /UP Ϫ/Ϫ platelets, confirming that the release of this metabolite by platelets is responsible for the enhancement of ROS generation. The ROS scavenger N-acetylcysteine (10 mmol/L) abolished the upregulation of HO-1 and integrin ␤ 3 ( Figure 4G ), suggesting that ROS generation is a critical step controlling the upregulation of integrin ␤ 3 by platelet supernatants. Importantly, the integrin ␣ v ␤ 3 dependency of HUVEC migration promoted by protein-free platelet supernatants was confirmed using an inhibitory antibody for this integrin, 25 which reduced the promigratory effects of WT and TP Ϫ/Ϫ /UP Ϫ/Ϫ platelet supernatants to similar levels ( Figure 5 ). Finally, the physiological relevance of dRP release by platelets was investigated in vivo using a chick chorioallantoic membrane (CAM) vascularization assay. 26 In these experiments, filtered supernatants from WT thrombinstimulated platelets strongly stimulated local vascularization of the CAMs, whereas supernatants from TP 
Discussion
Our results demonstrate that platelets release small molecules capable of increasing endothelial cell migration in vitro and provide evidence for the importance of dRP in mediating this response. Thus, the genetic ablation of dRP-generating TP and UP in mouse platelets or the specific inhibition of dRP-generating UP by PTAU in human platelets resulted in significantly reduced ability of protein-free supernatants to induce endothelial transmigration. Similarly, the genetic ablation of dRP-generating TP and UP in mouse platelets reduced the ability of protein-free platelet supernatants to promote endothelial monolayer repair in vitro. Both observations supported the conclusions that dRP at the concentrations released by platelets stimulates endothelial cell migration and that UP is the most important enzyme for platelet generation of this metabolite. In accordance with these conclusions, the addition of exogenous dRP to protein-free platelet supernatants reversed the inhibitory effects that pharmacological or genetic UP impairment produced on the stimulation of endothelial cell migration. Interestingly, the addition of dRP to the supernatants from resting platelets only partially restored the transmigration levels compared with supernatants from stimulated platelets, which suggested that other small molecules released by stimulated platelets synergize with dRP and are also necessary for maximal stimulation of endothelial cell motility (eg, sphingosine-1-phosphate 12 ).
The upregulation of integrin ␤ 3 in response to dRP has been reported to account for the increase in HUVEC motility induced by endothelial progenitor cells. 23 Here, we observed that platelet dRP also promotes endothelial cell motility via upregulation of integrin ␤ 3 , which is known to play a pivotal role in the stimulation of endothelial cell motility and angiogenesis. 27 Our data obtained using the inhibitory antibody LM609 show that the integrin heterodimer ␣ v ␤ 3 mediates the promotion of endothelial cell motility by protein-free platelet supernatants and suggest that the activity of this macromolecular complex is enhanced by dRP-dependent upregulation of integrin ␤ 3 . Moreover, LM609 reduced the HUVEC monolayer repair rate below levels observed in the presence of vehicle, suggesting a role for integrin ␣ v ␤ 3 in endothelial cell motility independently of platelet-dependent modulation of integrin ␤ 3 expression. In common with dRP, deoxyribose (dR) has also been shown to stimulate endothelial cell migration through integrins, in particular ␣ v ␤ 3 and ␣ 5 ␤ 1 . 28 Because the functional interaction of integrin ␣ v ␤ 3 with VEGF receptor-2 has been proposed to regulate VEGFinduced endothelial cell migratory activity, 29 it is not unreasonable to speculate that the upregulation of endothelial cell integrin ␤ 3 by platelet-derived dRP may enhance responsiveness to endogenous VEGF, resulting in increased endothelial cell motility and stimulation of angiogenesis. Interestingly, platelet preparations used to enhance tissue repair in clinical practice have been shown to stimulate angiogenesis via upregulation of integrin ␣ v ␤ 3 . 30 Previous studies in cancer cells have linked dRP production to protein glycation and generation of ROS. 31 Here, we showed that dRP increases ROS production in HUVECs, which is accompanied by induction of the antioxidant defense enzyme HO-1. Our experiments with the ROS inhibitor N-acetylcysteine suggest that the generation of ROS is necessary for dRP-dependent upregulation of integrin ␤ 3 by platelet supernatants. Although the precise mechanism coupling increased ROS production with enhanced integrin expression requires further investigation, our results provide strong support for ROS-dependent regulation of integrin ␤ 3 as a key pathway mediating the proangiogenic effects of platelet-derived dRP on endothelial cells.
Our data on the stimulation of neoangiogenesis in vivo by platelet-derived dRP are in accordance with previous studies highlighting a link between dRP and angiogenesis. TP, for example, was initially cloned as platelet-derived endothelial cell growth factor and characterized for its proangiogenic properties. 32 The local injection of TP or TP-expressing cells has also been shown to induce tissue neovascularization in vivo, and this depends on the enzy- matic activity of TP and the generation of dRP and its dephosphorylation product dR. [33] [34] [35] [36] Taken together, the data presented in this study show for the first time that platelets are capable of inducing endothelial cell migration and angiogenesis by releasing dRP, a proangiogenic metabolite that promotes the upregulation of integrin ␤ 3 in an ROS-dependent manner. These findings shed new light on the emerging importance of platelets as regulators of endothelial cell function and angiogenesis. In addition to stimulating angiogenesis during tissue repair, the effects of HO-1 (F and G) was assessed by immunoblotting. All blots were also reprobed for actin. E, The rate of intracellular ROS generation in HUVEC cells was measured using dihydroethidium (DHE, 10 mol/L). Traces shown in panels i and ii indicate the rates of ROS production before and after addition of 100 mol/L dRP or 1 mmol/L glucose, respectively. The rate of ROS generation in the absence or presence of dRP and glucose is measured as fluorescence units per second and is presented as meanϮSEM (nϭ6) in panel iii. Statistical significance was tested by 1-way ANOVA with the Bonferroni post test (*PϽ0.05).
platelet-derived dRP on endothelial cell motility may also be relevant in the context of angiogenesis-dependent pathologies characterized by increased local and systemic platelet activation (eg, cancer, atherosclerosis, and inflammation).
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